In this article, we will take a look at the 5 Most Promising Biotech Stocks to Buy Now. For a deeper discussion and an extended list, please see the 8 Most Promising Biotech Stocks to Buy Now.
louis-reed-pwcKF7L4-no-unsplash
5. Genmab A/S (NASDAQ:GMAB)
On May 8, Morgan Stanley reduced its price goal on Genmab A/S (NASDAQ:GMAB) to $33 from $34. It maintained an “Equal Weight” rating on the shares.
On May 7, Genmab A/S (NASDAQ:GMAB) reported revenue of $896 million for Q1 2026, rising 25% from $715 million a year earlier. The growth was because of higher DARZALEX and Kesimpta royalties and solid EPKINLY sales. Royalty income did the heavy lifting, soaring to $742 million from $589 million, as underlying drug sales expanded.
Costs climbed too, as Genmab A/S (NASDAQ:GMAB) reported operating expenses of $606 million, growing by 25%, showing pipeline growth and marketing investments. Profit held steady, posting an operating profit of $180 million compared to $188 million last year, while adjusted operating profit reached $237 million, up from $191 million.
Jan van de Winkel said Genmab A/S (NASDAQ:GMAB) made “tangible progress,” pushing late-stage programs and preparing for launches. It maintained 2026 guidance.
Genmab A/S (NASDAQ:GMAB) is a global biotechnology company that works on the development of human antibody therapies for cancer and other diseases.
4. Insmed Incorporated (NASDAQ:INSM)
On May 7, Insmed Incorporated (NASDAQ:INSM) reported first-quarter 2026 financials. The company posted a total revenue of $306.0 million because of BRINSUPRI generating $207.9 million and ARIKAYCE contributing $98.1 million. BRINSUPRI revenue surged 44% sequentially from Q4 2025, while ARIKAYCE rose 6% YoY, showing international expansion.
Will Lewis, CEO, said in the release that commercial momentum and pipeline progress continued to build, spotlighting BRINSUPRI’s launch path and ENCORE data strength. Insmed Incorporated (NASDAQ:INSM) also stated that the study fulfilled its primary and all multiplicity-controlled secondary goals. It prepared ARIKAYCE for an SNDAs filing with the FDA in the second half of 2026.
Guidance remained solid. The company reiterated its forecasts for BRINSUPRI revenue of at least $1 billion in 2026 and ARIKAYCE sales of $450 million to $470 million. It also launched the Phase 3 PALM-PAH study of TPIP in April, adding to its late-stage pipeline.
Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company that produces and markets medicines for rare diseases. It focuses on the Brensocatib and Treprostinil Palmitil Inhalation Powder pipelines.
3. BeOne Medicines AG (NASDAQ:ONC)
On May 8, Morgan Stanley raised its price target for BeOne Medicines AG (NASDAQ:ONC) from $389 to $395. It retained an “Overweight rating” on the shares.
On May 7, 2026, Morningstar reported that BeOne Medicines AG (NASDAQ:ONC) posted first-quarter GAAP net income of $227.4 million, surging from $1.3 million a year earlier. The revenue climbed by 35% because of strong flagship cancer drug sales expanding across the U.S. and Europe.
Profitability sharpened, posting adjusted EPS of $3.24, the company said.
Chief executive John V. Oyler said in the filing that earnings supported continued global growth, while Nomura analyst Jialin Zhang called the guidance raise “satisfactory,” backing a positive view, Dow Jones reported.
The company also recently landed a global licensing agreement with Chinese biotech firm Huahui Health worth up to $1.9 billion for exclusive rights to an oncology treatment. It joined a growing list of global biopharma companies looking to capitalize on China’s emerging pipeline of novel drugs.
BeOne Medicines AG (NASDAQ:ONC) is a global oncology company. It is based in Switzerland and concentrates on discovering and creating treatments that are cheaper and more accessible to cancer patients around the world.
2. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
On May 1, Morgan Stanley bumped up its price goal on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $370 from $360. It maintained an Equal Weight rating on the stock.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported first quarter 2026 financials, delivering global net product revenues of $1.036 billion, climbing 121% year over year. This was powered by total TTR revenues of $910 million that surged 153%. That momentum came largely from AMVUTTRA contributing $890 million, with ONPATTRO adding $20 million, together anchoring the TTR franchise.
M.D Chief Executive Officer of Alnylam, Yvonne Greenstreet, said in the company’s statement that the quarter marked “over $1 billion in quarterly product revenues for the first time.” She pointed to ongoing progress across Phase 3 and Phase 1 pipeline programs.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reiterated its 2026 outlook, guiding for $4.9 billion to $5.3 billion in total net product revenues. It includes $4.4 billion to $4.7 billion from TTR products.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) develops and markets RNA interference-based therapeutics. The company is headquartered in Cambridge, MA.
1. argenx SE (NASDAQ:ARGX)
On May 9, argenx SE (NASDAQ:ARGX) reported that the U.S. Food and Drug Administration approved a label expansion for Vyvgart and Vyvgart Hytrulo. It extended use across all serotypes of adult generalized myasthenia gravis, including anti-AChR, anti-MuSK, anti-LRP4, and triple seronegative patients.
On May 7, argenx SE (NASDAQ:ARGX) reported first-quarter 2026 financials, posting $1.3 billion in global product net sales, up 63% year over year, while flagging a May 10, 2026, PDUFA date for seronegative gMG. CEO Karen Massey said argenx “continues to deliver meaningful impact,” citing a 17th consecutive quarter of VYVGART growth and pointing to expansion across MG populations.
Argenx said it expects myositis topline data in the third quarter and MMN readouts in the fourth quarter of 2026 while advancing FcRn programs, including Phase 3-ready ARGX-213. Management added that it aims to treat 50,000 patients globally and secure 10 labeled signs by 2030, the company said.
argenx SE (NASDAQ:ARGX) is a global immunology company that works to improve the lives of people suffering from severe autoimmune diseases. It is operated in the United States, Japan, EMEA, and China.
While we acknowledge the potential of ARGX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARGX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen and 8 Best European Industrial Stocks to Buy Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
Hedge Fund Resource Center